Regeneron's 146.74% Volume Spike Elevates It to 172nd Rank as 1.64% Drop Reflects Pre-Data Market Uncertainty

On July 31, 2025, Regeneron Pharmaceuticals (REGN) traded with a volume of $0.78 billion, a 146.74% increase from the previous day, ranking 172nd in market activity. The stock closed down 1.64%, reflecting mixed investor sentiment ahead of key clinical data releases.

Regeneron announced updates to two pivotal oncology trials. The Phase 3 OLYMPIA-5 study is evaluating odronextamab, a bispecific antibody targeting CD20 and CD3, in combination with lenalidomide for relapsed/refractory follicular lymphoma and marginal zone lymphoma. This open-label trial, expected to report primary outcomes by July 2025, could redefine treatment standards if the experimental therapy demonstrates superior efficacy compared to rituximab-based regimens.

Parallel progress was noted in the Phase 1b trial of linvoseltamab (REGN5458), a BCMA x CD3 bispecific antibody being tested for multiple myeloma. The study combines the drug with established therapies like daratumumab and carfilzomib. With recruitment ongoing and an estimated completion date in July 2025, successful outcomes may strengthen Regeneron’s competitive position in hematologic malignancies.

A recent FDA approval for the high-dose version of Eylea (aflibercept) in ophthalmology was highlighted as a potential growth driver, with analysts noting it could delay biosimilar competition. This approval, combined with ongoing government contracts for next-generation antibody therapies, positions the company to sustain revenue streams amid therapeutic advancements.

Backtested performance from 2022 to present for a strategy purchasing the top 500 high-volume stocks daily showed a 166.71% return, outperforming the benchmark by 137.53% with a Sharpe ratio of 1.14. The compound annual growth rate of 31.89% underscores the strategy’s ability to generate risk-adjusted returns through liquidity-focused positioning.